The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jun 29, 2026
· 5 min read
Quick Score
View full audit trail →
Zymeworks offers US$929-million for COPD drug maker Theravance
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.011
5,747 articles tracked
7-day bias trend
LcenterR
Article Excerpt
Zymeworks offers US$929-million for COPD drug maker Theravance
JAMESON BERKOW
CAPITAL MARKETS REPORTER
SEAN SILCOFF
TECHNOLOGY REPORTER
PUBLISHED 1 HOUR AGO
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
Vancouver-based cancer drug maker Zymeworks Inc. ZYME-Q is buying Theravance Biopharma Inc. for US$929-million in cash with financing from a major Canadian pension fund.
Zymeworks will pay US$17 per share for Dublin-based Theravance, which is actually a slight discount to the Irish company’s most recen…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.